Shares of Ardelyx dropped in after-market trading earlier this week after the AstraZeneca partner acknowledged that its lead drug tenapanor was unimpressive in a Phase IIa study.
Ardelyx, based in California, says that tenapanor missed the primary endpoint among 154 patients with Stage 3 chronic